Resources
Access our latest resources—including publications about our science, recent media, and conference presentations.
Mar 2023 | From Ikena Oncology
IK-595, a MEK-RAF complex inhibitor, obviates CRAF mediated resistance resulting in superior RAS/MAPK pathway inhibition and anti-tumor activity in RAS/RAF altered cancers
X. Michelle Zhang, PhD | AACR Special Conference: Targeting RAS
Mar 2023 | From Ikena Oncology
IK-595, A MEK/RAF Complex Inhibitor, Obviates CRAF Mediated Resistance Resulting in Superior RAS/MAPK Pathway Inhibition and Anti-tumor Activity in RAS/RAF Altered Cancers
Eric Haines | AACR Special Conference: Targeting RAS
Mar 2023 | From Ikena Oncology
The Ah Receptor from Toxicity to Therapeutics. Report from the 5th AHR Meeting at Penn State University, USA, June 2022
McGovern, K et al. | International Journal of Molecular Sciences
Nov 2022 | From Ikena Oncology
A Phase 1b open-label, single-arm dose expansion study of IK-175, an oral AHR inhibitor, in combination with nivolumab in patients with primary PD-1 inhibitor resistant advanced head and neck cancer
Trupti Lingaraj | SITC 2022
Nov 2022 | From Ikena Oncology
Initial results from a Phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma
David H. Aggen, M.D., Ph.D. | SITC 2022
Oct 2022 | From Ikena Oncology
IK-930, a Novel TEAD-inhibitor, Overcomes Hippo/YAP-mediated Adaptive Response to MEK and EGFR-targeted Therapies
Mihir Rajurkar, Ph.D. | EORTC-NCI-AACR 2022
Jun 2022 | From the Media
FDA to Speed Up Review of Novel Drug for Mesothelioma Not Treatable by Surgery
CURE® | IK-930
Jun 2022 | From Ikena Oncology
Discovery and characterization of a novel aryl hydrocarbon receptor inhibitor, IK-175, and its inhibitory activity on tumor immune suppression
McGovern, K. et al. | Molecular Cancer Therapeutics
Jun 2022 | From Ikena Oncology
TRIAL IN PROGRESS: A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Anthony Tolcher, MD | ASCO Annual Meeting 2022
Jun 2022 | From Ikena Oncology
TRIAL IN PROGRESS: A Phase 1a/b Open Label Study of IK-175, an Oral AHR Inhibitor, Alone and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
David H. Aggen, MD, PhD | ASCO Annual Meeting 2022
